© 2021 MJH Life Sciences and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
© 2021 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
An interview with Dr. Luhua (Michael) Wang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center
Don’t let your disease define you
October 18th 2021, 1:00pm
More selective BTK inhibitors like Brukinsa may give patients with mantle cell lymphoma who progressed on prior therapies another option with potentially fewer and more manageable side effects.
September 17th 2021, 1:00pm
After determining an aggressive or non-aggressive treatment approach to mantle cell lymphoma, patients and clinicians must then discuss COVID-19 vaccine efficacy when determining a maintenance treatment strategy.
September 15th 2021, 9:00pm
Tecartus was the first CAR-T cell therapy to be approved for the treatment of recurrent mantle cell lymphoma. Now, more than a year after its approval, a doctor discusses his experience prescribing the drug.
August 19th 2021, 9:00pm
Patients who are immunocompromised, such as patients with blood cancers, may get the boosted immunity needed to reduce their risk for contracting COVID-19 and hospitalization for compilations related to the virus.
August 4th 2021, 7:00pm
Some patients with mantle cell lymphoma can opt for a wait-and-watch approach, while others will need more aggressive treatment.
July 26th 2021, 1:00pm
About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.
July 16th 2021, 10:00pm
When patients with mantle cell lymphoma are discussing the use of a BTK inhibitor, they must consider what their insurance will cover, as well as current health complications and potential side effects.
July 14th 2021, 6:00pm
Patients can now prioritize whether durable responses to treatment or avoiding certain side effects are more valuable to them.
July 13th 2021, 11:00pm
Patients with mantle cell lymphoma whose disease relapses within a year and a half of transplant tend to have worse outcomes and may want to consider new treatment regimens.
July 2nd 2021, 9:00pm
The Food and Drug Administration granted a breakthrough therapy designation to a new drug that can be used to treat patients with mantle cell lymphoma.
What Does It Mean to Be a Cancer Survivor?
Becoming an Informed Patient With Rare Cancer
A Step-by-Step Guide to Cancer Genetic Testing
Experiencing Invalidation After a Stage 0 Breast Cancer Diagnosis